Listeria News and Research

RSS

Listeria is a bacterial genus containing seven species. Named after the English pioneer of sterile surgery, Joseph Lister, Listeria species are Gram-positive bacilli and are typified by ''L. monocytogenes'', the causative agent of listeriosis.

MIT featured in U.S. Equity News

Micro Identification Technologies, Inc., a leader in rapid bacterial identification, today announces it was recently featured in an editorial published by U.S. Equity News that covers the history of bacteria, its life threatening effects, and publicly traded companies leading the fight against harmful bacteria.

12 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Some components of the onion have antioxidant and antimicrobial properties, making it possible to use this bulb for food preservation. This is demonstrated by researchers from the Polytechnic University of Catalu-a and the University of Barcelona in a study that has just been published in the International Journal of Food Science and Technology.

16 Apr 2010

Escherichia coli cases drop in 2009

As per a report from the Centers for Disease Control and Prevention (CDC) a 12 % drop in rates of Escherichia coli (E.coli) infection has been noted in 2009 as compared to statistics for 2008. This is being seen by federal health officials as a sign that the new food safety measures are effective. Most of the pathogens under study are from the bacteria family like E.coli 0157, salmonella, campylobacter, listeria and vibrio. It was found that food poisoning rates for the most common pathogens have changed little from statistics collected in 2004.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

DIATHERIX GI test panel can detect nine types of GI infections

DIATHERIX Laboratories adds a gastrointestinal panel to its lineup of highly sensitive, rapid response diagnostic tests. In a single result, the DIATHERIX GI panel can detect and differentiate nine types of GI infections so physicians can quickly identify patients who have severe, life-threatening infections.

30 Mar 2010

FDA: Outbreak of campylobacteriosis linked to drinking raw milk

The U.S. Food and Drug Administration, along with several state agencies, is alerting consumers to an outbreak of campylobacteriosis associated with drinking raw milk. At least 12 confirmed illnesses have been recently reported in Michigan. Symptoms of campylobacteriosis include diarrhea, abdominal pain and fever.

27 Mar 2010

AOAC Research Institute validates MicroSEQ Salmonella spp. Detection Kit

Life Technologies Corporation today announced that its Applied Biosystems MicroSEQ® Salmonella spp. Detection Kit has been validated by the AOAC Research Institute for detection of the bacteria Salmonella.

23 Mar 2010

Advaxis' ADXS11-001 Phase 1 study for cervix cancer failures: 13.3% of treated patients alive at over 3 years

Ongoing follow up of the surviving patients from the phase I study of ADXS11-001 for the treatment of cervix cancer failures conducted by Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has shown that two of fifteen treated patients or 13.3% are still alive 1,248 and 1,128 days after receiving their initial dose.

23 Mar 2010

Activeion Cleaning Solutions announces new European subsidiary, Activeion GmbH

Activeion Cleaning Solutions LLC, Rogers, MN USA is proud to announce its new European subsidiary, Activeion (Europe) GmbH. Activeion (Europe) GmbH will distribute and market the ionator EXP™ throughout Europe, the Middle East and Africa. Activeion's ionator EXP™ is a handheld, on-demand, completely chemical-free cleaning tool that activates and converts tap water into ionised water, a powerful dirt-removing and bacteria-killing product.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

Norgen Biotek launches over 30 new kits for NA based diagnostics

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 30 new kits for nucleic-acid based diagnostics. Norgen makes best-in-class kits for nucleic acid and protein sample preparation, and has recognized that high quality sample preparation is the key to high quality diagnostics.

19 Mar 2010

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Cost-effective technology that allows products to be traced through the U.S. supply chain might have helped contain the spread of hydrolyzed vegetable protein products contaminated with Salmonella, Intelligent Global Pooling Systems announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending to overhaul the nation's food safety law.

15 Mar 2010

Advaxis develops long-term, room temperature, storage-stable form of its vaccines

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.

12 Mar 2010

Advaxis confirms long-term stability of its first clinical formulation of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has confirmed the long-term stability of its first clinical formulation of ADXS11-001, the Company’s lead immunotherapeutic.

9 Mar 2010

Threat of food supply contamination: National sanitary standards on pallet industry needed

The need to set national sanitary standards on the pallet industry to curb the threat of contamination to the U.S. food supply was drawn into sharp relief by a just-issued report by the Produce Safety Project showing acute foodborne illness costs the nation $152 billion annually in healthcare, workplace and other economic losses.

6 Mar 2010

Advaxis' Listeria based fusion protein granted U.S. patent

The US Patent and Trademark Office (USPTO) has issued Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, patent #7662396 titled “Compositions and Methods for Enhancing the Immunogenicity of Antigens” for the use of fusion proteins that have been found to be effective in numerous models for the treatment of cancer in the presence of immune tolerance.

5 Mar 2010

Advaxis reports net income of $929,244 for year ended October 31, 2009

Advaxis, Incorporated, the live, attenuated Listeria monocytogenes immunotherapy company, today reported results for the fiscal year-ended October 31, 2009.

19 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Studies suggest potential therapeutic targets for food poisoning, TB and autoimmune diseases

Researchers at National Jewish Health have discovered how the virulent food-borne bacteria Listeria monocytogenes induces infected immune cells to sabotage their own defensive response.

2 Feb 2010